Monthly Archives: June 2022

Rescheduled to June 16, 2022, at 1:00pm Eastern Time Rescheduled to June 16, 2022, at 1:00pm Eastern Time

More here:
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting

New York, NY, and Tel Aviv, ISRAEL, June 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its academic partner, Dr. Thomas Arendt at Leipzig University, has completed full enrollment for 2nd cohort (confirmatory) for the ongoing clinical trial to evaluate the concordance of the LymPro Alzheimer’s Blood Test scores with amyloid PET imaging scores. The Company expects the data to be released in the summer of 2022.

See the rest here:
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 2022 Jefferies Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a presentation at 8:00 am Eastern Time on Friday, June 10, 2022, at the Marriott Marquis in New York, New York. Drs. Lim and Chacko will also participate in one-on-one investor meetings.

The rest is here:
Erasca to Present at the 2022 Jefferies Healthcare Conference

Company announcement – No. 26 / 2022

Read more from the original source:
Zealand Pharma completes registration of capital increase

SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the first subject was dosed in a Phase I clinical study (NCT05364840) of its oral main viral protease (Mpro) inhibitor, STI-1558.

See the original post here:
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and...

MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that management will participate at two upcoming conferences in June:

The rest is here:
Elucida Oncology to Present at Two Upcoming Conferences

See the article here:
Virbac : Declaration of the number of shares and voting rights 05/2022

See the article here:
Bavarian Nordic Conference Call: General Monkeypox Update

Ad hoc announcement pursuant to Art. 53 LR

Read the original:
Santhera Announces Corporate Calendar Update

Saint-Herblain (France), June 3, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at the Jefferies Healthcare Conference which will take place from June 8 to 10, 2022 in New York.

See original here:
Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare Conference